NCT00452790View on ClinicalTrials.gov

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

PHASE3CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

February 28, 2010

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

1 dose at 6, 10, 14 weeks and 12 months of age

BIOLOGICAL

7 valent pneumococcal conjugate vaccine

1 dose at 6, 10, 14 weeks and 12 months of age

Trial Locations (12)

141008

Ludhiana

160031

Sector-32 B

411001

Pune

411011

Pune

560017

Bangalore

600034

Chennai

160 012

Sector-12

560 034

Bangalore

400 026

Mumbai

411 043

Pune

110 060

Rajinder Nagar

632 004

Vellore

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00452790 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India | Biotech Hunter | Biotech Hunter